Literature DB >> 8817087

Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry.

M A King1, M A Radicchi-Mastroianni.   

Abstract

The blood of multiple myeloma patients was examined for non-MHC-restricted cytotoxic lymphocytes. Four colour flow cytometry was used to phenotype the cells within a light scatter gate large enough to include all lymphocytes. NK and T cells were identified using CD16, CD56, and CD3 antibodies, and myeloid cells with CD13 and CD14 antibodies. Three subpopulations of NK cells and 3 subpopulations of CD16+ or CD56+ T cells were enumerated. The CD56+ NK and T cells were also examined with CD69, CD25, and anti-HLA-DR antibodies to assess their activation state. We found no evidence that either the percentage or the absolute number of any subpopulation of the NK cells or CD56+ T cells correlated with disease activity. Neither did we find any significant abnormalities in the numbers of activated CD56+ NK or T cells. We conclude that it is unlikely that circulating non-MHC-restricted cytotoxic lymphocytes are responsible for maintaining disease stability in myeloma patients with indolent disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8817087     DOI: 10.1002/(SICI)1097-0320(19960615)26:2<121::AID-CYTO4>3.0.CO;2-J

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  8 in total

1.  Characterization of human peritoneal dendritic cell precursors and their involvement in peritonitis.

Authors:  M L McCully; T A Chau; P Luke; P G Blake; J Madrenas
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

Authors:  Vladimir Jurisic; Tatjana Srdic; Gordana Konjevic; Olivera Markovic; Milica Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

Review 3.  The role of natural killer T cells in B cell malignancies.

Authors:  Ghasem Ghalamfarsa; Abolghasem Hadinia; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2013-03-19

4.  Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds.

Authors:  Kathryn Lagrue; Alex Carisey; David J Morgan; Rajesh Chopra; Daniel M Davis
Journal:  Blood       Date:  2015-05-22       Impact factor: 22.113

Review 5.  The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Authors:  T Dosani; M Carlsten; I Maric; O Landgren
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

Review 6.  Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.

Authors:  Gianfranco Pittari; Luca Vago; Moreno Festuccia; Chiara Bonini; Deena Mudawi; Luisa Giaccone; Benedetto Bruno
Journal:  Front Immunol       Date:  2017-11-07       Impact factor: 7.561

Review 7.  Monitoring NK cell activity in patients with hematological malignancies.

Authors:  Sébastien Viel; Emily Charrier; Antoine Marçais; Paul Rouzaire; Jacques Bienvenu; Lionel Karlin; Gilles Salles; Thierry Walzer
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

Review 8.  NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias.

Authors:  Renato Zambello; Gregorio Barilà; Sabrina Manni; Francesco Piazza; Gianpietro Semenzato
Journal:  Cells       Date:  2020-03-21       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.